Cargando…
The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation
The neuregulins (NRGs) represent a large family of membrane‐anchored growth factors, whose deregulation may contribute to the pathogenesis of several tumors. In fact, targeting of NRG‐activated pathways has demonstrated clinical benefit. To improve the efficacy of anti‐NRG therapies, it is essential...
Autores principales: | Centa, Ariana, Rodríguez‐Barrueco, Ruth, Montero, Juan Carlos, Pandiella, Atanasio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026874/ https://www.ncbi.nlm.nih.gov/pubmed/29683256 http://dx.doi.org/10.1002/1878-0261.12310 |
Ejemplares similares
-
Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
por: Ocaña, Alberto, et al.
Publicado: (2016) -
Neuregulin-1-mediated ErbB2–ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation
por: Fock, Valerie, et al.
Publicado: (2015) -
On the Modulatory Roles of Neuregulins/ErbB Signaling on Synaptic Plasticity
por: Ledonne, Ada, et al.
Publicado: (2019) -
Clozapine-dependent inhibition of EGF/neuregulin receptor (ErbB) kinases
por: Kobayashi, Yutaro, et al.
Publicado: (2019) -
Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)